|
|
Article: Amgen Wins Oncology Label For Aranesp Against Anemia.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Amgen Inc.'s Aranesp (darbepoetin alpha) for oncology applications won FDA approval, and the competitive race that began last year between the company and erythropoietin licensee Johnson & Johnson will begin heating up shortly.
"Oncologists are using Aranesp now and they can continue to," said Michael Beckerich, spokesman for Thousand Oaks, Calif.-based Amgen. "Now we can actually talk about it, whereas before we had to let the data speak for itself." Aranesp for the new indication may be launched by the end of this month, he added.
The approval came as no surprise for many analysts. Amgen's stock (NASDAQ:AMGN) closed Monday ...